Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

The case for Eli Lilly To be fair, while Novo Nordisk has the lead in the GLP-1 arena, I have to note that Lilly's Mounjaro and Zepbound have not been on the market nearly as long as its ...

Eli Lilly has recently entered the weight loss space through its competing GLP-1 medications, Mounjaro and Zepbound. Both companies are currently generating abnormally high growth as demand for ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs ...

Learn More » Zepbound conclusively beats Wegovy In December, Eli Lilly released top-line data from a phase 3 clinical trial that pitted its weight loss medicine Zepbound with Novo Nordisk's Wegovy.

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...